Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models

被引：0
|
作者：
Matsuki, Masahiro
Yamamoto, Yuji
Hoshi, Taisuke
Kimura, Takayuki
Funahashi, Yasuhiro
Matsui, Junji
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1805
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1805
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine
    Jian, Weiguo
    Yamashita, Hideyuki
    Levitt, Jonathan M.
    Lerner, Seth P.
    Sonpavde, Guru
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) : 1772 - 1778
  • [42] The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
    Zhu, Jie
    Fang, Peiqi
    Wang, Chong
    Gu, Meixiu
    Pan, Baishen
    Guo, Wei
    Yang, Xinrong
    Wang, Beili
    CANCER MEDICINE, 2021, 10 (22): : 7977 - 7987
  • [43] Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma
    Pe, Jason
    Choi, Bongseo
    Choi, Hyunjun
    Kwon, Soon Woo
    Kim, Dong-Hyun
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 45 (12) : 1834 - 1841
  • [44] Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma
    Jason Pe
    Bongseo Choi
    Hyunjun Choi
    Soon Woo Kwon
    Dong-Hyun Kim
    CardioVascular and Interventional Radiology, 2022, 45 : 1834 - 1841
  • [45] Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
    Takeda, Haruhiko
    Nishijima, Norihiro
    Nasu, Akihiro
    Komekado, Hideyuki
    Kita, Ryuichi
    Kimura, Toru
    Kudo, Masatoshi
    Osaki, Yukio
    HEPATOLOGY RESEARCH, 2019, 49 (05) : 594 - 599
  • [46] Lenvatinib for Hepatocellular Carcinoma: A Literature Review
    Hatanaka, Takeshi
    Naganuma, Atsushi
    Kakizaki, Satoru
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 20
  • [47] Lenvatinib mesylate to treat hepatocellular carcinoma
    Ielasi, L.
    Tovoli, F.
    Piscaglia, F.
    DRUGS OF TODAY, 2019, 55 (05) : 305 - 313
  • [48] In Vivo and in vitro antitumor activity of tomatine in hepatocellular carcinoma
    Echeverria, Cesar
    Martin, Aldo
    Simon, Felipe
    Salas, Cristian O.
    Nazal, Mariajesus
    Varela, Diego
    Perez-Castro, Ramon A.
    Santibanez, Juan F.
    Valdes-Valdes, Ricardo O.
    Forero-Doria, Oscar
    Echeverria, Javier
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [49] Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
    Jo, Jae-Cheol
    Choi, Eun Kyoung
    Shin, Jae-Sik
    Moon, Jai-Hee
    Hong, Seung-Woo
    Lee, Ha-Reum
    Kim, Seung-Mi
    Jung, Soo-A
    Lee, Dae-Hee
    Jung, Seang Hwan
    Lee, Sun-Hye
    Kim, Jeong Eun
    Kim, Kyu-Pyo
    Hong, Yong Sang
    Suh, Young-Ah
    Jang, Se Jin
    Choi, Eun Kyung
    Lee, Jung Shin
    Jin, Dong-Hoon
    Kim, TaeWon
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) : 2613 - 2622
  • [50] Antitumor activity of Chidamide in hepatocellular carcinoma cell lines
    Wang, Haijuan
    Guo, Yi
    Fu, Ming
    Liang, Xiao
    Zhang, Xueyan
    Wang, Renzhi
    Lin, Chen
    Qian, Haili
    MOLECULAR MEDICINE REPORTS, 2012, 5 (06) : 1503 - 1508
12345